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Methods	 219	 COPD	 patients	 (FEV1:	 42±16%	 predicted)	 with	 inspiratory	 muscle	 weakness	 (PImax:	
51±15	 cmH2O)	were	 randomised	 into	 an	 intervention	 group	 (IMT	 +	 PR;	 n=110)	 or	 a	 control	 group	
(Sham-IMT	+	PR;	n=109)	 in	this	double	blind,	multicentre	RCT	between	February	2012	and	October	
2016	 (ClinicalTrials.gov	NCT01397396).	 Improvement	 in	six-minute	walking	distance	 (6MWD)	was	a	
priori	defined	as	the	primary	outcome.	Pre-specified	secondary	outcomes	included	respiratory	muscle	
function	and	endurance	cycling	time.	
Findings	 No	 significant	 differences	 between	 the	 intervention	 group	 (n=89)	 and	 the	 control	 group	
(n=85)	 in	 improvements	 in	6MWD	were	observed	 (0.3m,	95%CI:	 -13	 to	14;	p=0.967).	Patients	who	
completed	assessments	in	the	intervention	group	achieved	larger	gains	in	inspiratory	muscle	strength	





additional	 improvements	 in	 6MWD	 (primary	 outcome).	 Additional	 gains	 in	 endurance	 time	 and	


























and	 clinically	 relevant	 improvements	 in	 exercise	 capacity	 and	 health-related	 quality	 of	 life.[7,	 8]	
Inspiratory	muscle	 training	 (IMT)	has	been	extensively	 studied	 in	 the	 last	 decades	 in	patients	with	
COPD.[9]	 However,	 due	 to	 differing	 interpretations	 of	 the	 existing	 evidence,	 in	 combination	 with	
limited	resources	and	time	constraints	during	PR	programme,	this	adjunctive	therapy	is	at	this	moment	
not	 included	 in	 about	 50%	 of	 these	 programmes.[9-14]	 IMT	 as	 a	 standalone	 therapy	 improves	
inspiratory	 muscle	 function	 (strength	 and	 endurance),	 decreases	 symptoms	 of	 dyspnoea,	 and	
improves	exercise	capacity.[9]	The	value	of	adjunctive	IMT	during	PR	is	less	clear.	While	adjunctive	IMT	
in	combination	with	GET	resulted	in	significant	additional	improvements	in	respiratory	muscle	function	
beyond	 the	 effects	 of	GET	 alone,	 its	 additional	 effects	 on	 outcomes	 such	 as	 exercise	 capacity	 and	
quality	of	life	are	insufficiently	supported	by	data	so	far.[7,	9]	Based	on	subgroup	analyses	in	meta-
analyses	 and	general	 physiological	 considerations	 it	 has	been	 recommended	 that	 future	 studies	of	
adjunctive	 IMT	 in	 patients	 with	 COPD	 should	 focus	 specifically	 on	 patients	 with	 exercise	 induced	
dyspnea	and	inspiratory	muscle	weakness.[7,	9,	15]		
The	 present	 study	 examined	 the	 effects	 of	 adding	 a	 largely	 unsupervised,	 but	 well-controlled	
adjunctive	 IMT	 programme	 in	 the	 context	 of	 an	 adequately	 powered,	 multicentre,	 double-blind,	
randomised	controlled	trial	design,	in	selected	COPD	patients	with	inspiratory	muscle	weakness.	We	








The	 study	 was	 approved	 centrally	 by	 the	 University	 Hospital	 Leuven’s	 Institutional	 Review	 Board	




More	 information	about	study	procedures	can	be	 found	 in	an	extended	MATERIAL	AND	METHODS	
section	and	in	a	video	tutorial	(see	supplementary	video	files	1,	2,	3,	and	4),	as	well	as	in	a	previously	
published	study	protocol.[16]	
Interventions.	Both	groups	performed	an	 identical	general	exercise	 training	 (GET)	programme.	The	
training	volume	ranged	from	20	sessions	(Germany),	to	36	sessions	(other	centres).	Training	frequency	
ranged	from	three	to	five	sessions	per	week.	Duration	of	training	sessions	was	around	60	minutes.	
Patients	performed	endurance	 training	or	 interval	 training	at	moderate	 to	high	 intensities	Training	
intensities	during	GET	were	progressively	 increased	during	 the	course	of	 the	programme	based	on	
symptom	scores.	Training	 intensities	corresponded	to	Borg	CR-10	Scale	ratings	of	4–6	on	dyspnoea	
sensation.[16]	 Physiotherapists	 providing	 this	 intervention	 were	 blinded	 to	 group	 allocation	 of	
patients.	All	participants	(intervention	and	control	group)	were	led	to	believe	that	they	followed	an	
active	adjunctive	 IMT	 intervention	during	 the	GET	 intervention.	This	was	done	 in	order	 to	 improve	
adherence	with	the	intervention	in	the	control	group	and	to	ensure	placebo	treatment	effects	in	both	
groups.[17]	 IMT	 in	 both	 groups	 was	 performed	 daily,	 using	 the	 PowerBreathe	 KHP2	 device	
(POWERbreathe®KHP2,	 HaB	 International	 Ltd.,	 Southam,	 UK)	 according	 to	 previously	 described	





data	 on	 training	 quality	 during	 the	 unsupervised	 sessions	 were	 reviewed	 and	 patients	 received	
instructions	and	 feedback	on	how	 to	optimize	 their	home	 training	efforts.	Training	 intensity	 in	 the	





according	 to	 a	 standardized	 published	 protocol	 and	 related	 to	 reference	 values.[19]	 Secondary	











not	 consider	 patients	 who	 had	 missing	 outcome	 data	 due	 to	 loss	 to	 follow	 up	 in	 the	 analysis.	
Consequently	no	imputation	for	missing	data	was	performed	and	a	so	called	‘complete	/	available	case	
analysis’	was	performed.[21]	The	missing	data	was	 interpreted	as	 ‘missing	at	 random’.	Differences	
between	 groups	 after	 the	 intervention	 were	 compared,	 adjusting	 for	 values	 of	 the	 respective	
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outcomes	 at	 baseline,	 using	 analysis	 of	 covariance	 (ANCOVA).[22]	 Because	 randomisation	 was	
performed	 by	 centre,	 the	 adjustment	 by	 centre	 was	 tested.	 Additional	 exploratory	 analyses	 were	
performed	 to	 study	 1)	 the	 impact	 of	 IMT	 characteristics	 on	 improvements	 in	 PImax	 and	 2)	 the	
relationship	between	improvements	in	PImax	and	GET	outcomes.	More	details	on	analyses	by	‘centre’	
and	exploratory	analyses	are	provided	 in	 the	online	data	supplement.	To	account	 for	 the	potential	
impact	of	differences	in	training	volume	between	GET	programme	offered	in	the	different	centres	on	
outcomes	we	also	tested	the	effect	of	‘centre’	on	treatment	effects	using	centre*intervention	effect.	












Changes	 in	 exercise	 capacity	 and	 GET	 progression.	 Results	 of	 different	 tests	 for	 exercise	 related	
outcomes	 are	 presented	 in	 Table	 2.	 No	 statistically	 significant	 between-group	 differences	 in	
improvements	 in	 6MWD	 (primary	 outcome)	 were	 observed.	 Endurance	 cycling	 time	 (secondary	
outcome)	improvement	was	significantly	greater	in	the	intervention	group	with	significant	reductions	
in	 dyspnoea	 symptoms	 at	 iso-time	 during	 the	 test	 (Table	 2).	 Both	 cycling	 and	 treadmill	 training	





IMT	 progression.	 The	 intervention	 group	 completed	 79±4%	 of	 prescribed	 IMT	 sessions	 while	 the	
control	group	completed	81±4%	of	prescribed	sessions.	The	intervention	group	increased	their	training	
load	from	47±2%	of	their	baseline	PImax	in	the	first	week	of	training,	to	84±4%	of	their	baseline	PImax	
in	week	 12	 (see	 Figure	 E2	 in	 the	 online	 data	 supplement).	 Data	 on	 the	weekly	 sum	 of	 total	work	
performed	during	all	 IMT	sessions	(based	on	pressure	and	volume	data	recorded	and	stored	by	the	
training	devices)	is	presented	in	Figure	2.	The	average	Borg	CR-10	scale	inspiratory	effort	scores	for	
breathing	 during	 the	 final	 minute	 of	 the	 supervised	 IMT	 sessions	 were	 3.5±0.3	 and	 2.6±0.3	 for	
intervention	and	control	group,	respectively.		
















Impact	 of	 centre	 on	 outcomes.	 Interactions	 between	 centres	 and	 between-group	 post-treatment	







during	 IMT	sessions	(i.e.	 total	 inspiratory	work	performed	per	session	and	average	peak	power	per	
session)	 and	 progression	 in	 training	 intensity	 were	 significantly	 related	 to	 the	 magnitude	 of	
improvements	achieved	in	PImax	(Figure	3A-3C).	Conversely,	average	training	volume	(the	number	of	
sessions	 stored	by	 the	TFRL	devices)	was	not	 significantly	associated	with	changes	 in	PImax	 (p-for-
trend=0.129).	 In	a	stepwise	multiple	 regression	analyses	 total	work	performed	during	 IMT	sessions	
(partial	 r-square:	 0.24),	 baseline	 PImax	 (partial	 r-square:	 0.08)	 and	 training	 compliance	 (partial	 r-
square:	0.01)	were	significantly	related	to	the	improvements	in	PImax	after	training	(F(3,	139)	=	22.9,	
p<0.001,	R2=0.33).	More	detailed	results	of	 the	regression	analyses	are	provided	 in	Table	E5	 in	 the	

















intervention	 group	 and	 the	 control	 group	 were	 both	 equally	 large	 and	 fall	 within	 the	 range	 of	 a	
minimum	clinically	important	difference	(MCID)	of	25-35m.[23]	These	findings	are	in	line	with	results	
from	 a	 recent	 systematic	 review	 of	 RCT’s	 studying	 adjunctive	 interventions	 during	 pulmonary	
rehabilitation.	 In	 this	 meta-analysis	 none	 of	 the	 studied	 adjunctive	 interventions	 (e.g.	 leg	 muscle	
strength	training,	inspiratory	muscle	training,	non-invasive	ventilation,	or	nutritional	supplementation)	
were	able	to	induce	statistically	significant	additional	improvements	in	6MWD.[24]	In	contrast	to	the	
results	of	 the	6MWD,	 significantly	 larger	 improvements	 in	 cycling	endurance	 time	and	 significantly	
greater	reductions	in	dyspnoea	symptoms	at	iso-time	were	observed	in	the	intervention	group.	The	
average	additional	improvement	in	endurance	cycling	time	of	75	seconds	falls	within	a	range	of	46	to	
105	 seconds	 that	 has	 recently	 been	 defined	 as	 a	 MCID	 for	 constant-load	 cycle	 endurance	 time	
improvements	 in	 response	 to	 pharmacological	 interventions.[25]	 The	 superior	 responsiveness	 of	





















larger	 improvements	 in	 the	 control	 group	 (17%	 in	 our	 study	 vs	 8%	 in	 the	meta-analysis)	might	 be	
explained	 by	 the	 fact	 that	 not	 all	 control	 groups	 in	 the	meta-analysis	 performed	 a	 sham	 training	















and	 respiratory	 muscle	 function	 we	 did	 not	 observe	 any	 further	 improvements	 in	 quality	 of	 life	
domains	(including	dyspnoea	subscales).	It	might	be	that	the	substantial	improvements	in	quality	of	
life	 scores	 in	 the	 control	 group	 in	 response	 to	 the	 comprehensive	 rehabilitation	 intervention	were	
already	 approaching	 the	 ceiling	 effect	 for	 improvement.	 In	 analogy	with	 the	 absence	of	 additional	
improvements	in	the	6MWD	this	might	be	related	to	a	limited	sensitivity	of	the	applied	questionnaire	
(CRQ)	to	pick	up	additional	improvements	on	top	of	an	already	very	significant	and	clinically	important	
effect.	 This	might	be	 improved	 in	 future	 studies	by	using	other	potentially	more	 sensitive	dyspnea	
scales.	One	option	would	be	to	use	scales	that	are	specifically	designed	to	detect	different	gradations	
of	 change	 like	 the	 transitional	 dyspnea	 index.[31]	 Another	 excellent	 emerging	 option	 is	 the	
multidimensional	 dyspnea	 profile	 which	 can	 be	 specifically	 focused	 to	 assess	 symptoms	 during	
predefined	periods	(e.g.	at	standardized	times	during	an	exercise	test).[32]	










during	 IMT	 (i.e.	 total	 inspiratory	work	 performed/session,	 average	 peak	 power/session)	 as	well	 as	
progression	of	training	intensity.	Our	results	emphasize	that	external	work	and	power	are	important	

















between	 group	 differences	 in	 several	 relevant	 outcomes	 (i.e.	 increases	 in	 PImax,	 bicycle	 exercise	
intensity	 during	 PR	 sessions,	 6MWD	 and	 endurance	 cycling	 time	 see	 Table	 E4	 in	 the	 online	 data	
supplement)	 compared	with	 the	centre	 that	offered	20	 sessions.	The	uniformity	of	 these	data	 (i.e.	
differences	in	these	variables	were	either	consistently	larger	or	smaller)	is	in	line	with	the	presented	
relationships	between	improvements	achieved	in	PImax	on	the	one	hand	and	the	ability	to	increase	
exercise	 intensity	 during	 GET	 and	 resulting	 improvements	 in	 exercise	 capacity	 on	 the	 other	 hand	
(Figure	 4).	 From	 these	 observations,	 we	 conclude	 that	 factors	 other	 than	 the	 number	 of	 sessions	
offered	(such	as	contrasts	in	symptom	based	training	intensity	during	general	exercise	training	sessions	
between	groups)	probably	contributed	to	the	interaction	between	centre	and	training	outcomes.		


























scales.[34]	 The	 fact	 that	 we	 observed	 slightly	 higher	 (though	 not	 significantly	 different)	 training	
intensities	 especially	 on	 the	 bicycle	 in	 the	 intervention	 group	 are	 another	 indirect	 indication	 that	





















the	 adjunctive	 intervention	 was	 not	 directly	 assessed.	 Finally	 we	 did	 not	 perform	 serial	 IC	










the	 same	 time	 we	 believe	 that	 the	 improvements	 in	 our	 secondary	 outcome	 (constant	 workrate	
endurance	cycling)	were	not	negligible	(50%	greater	than	rehabilitation	alone).	We	believe	that	this	is	
an	 important	 finding,	which	could	guide	 researchers	 towards	 identifying	more	appropriate	primary	
outcomes	 for	 future	 studies	 of	 adjunctive	 interventions	 to	 pulmonary	 rehabilitation.	 The	
multidimensional	 dyspnea	 profile	 [32]	 might	 be	 be	 an	 interesting	 option	 to	 assess	 differences	 in	
symptoms	 at	 standardized	 times	 during	 an	 exercise	 test.	 The	 overall	 good	 training	 compliance	
indicates	that	it	was	feasible	to	implement	this	adjunctive	IMT	intervention	on	a	relatively	large	scale.	
Across	 the	different	 centres	 it	was	 furthermore	 feasible	 to	 implement	 simple	and	 sensitive	 clinical	
assessments	of	respiratory	muscle	function	(both	strength	and	endurance).	The	study	also	highlights	
the	 benefits	 of	 closely	monitoring	 and	 controlling	 IMT	 sessions	 since	 both	 quality	 and	 intensity	 of	
training	 sessions	 were	 strongly	 associated	 with	 improvements	 in	 respiratory	 muscle	 function.	
Additionally,	 improvements	 in	 PImax	 were	 related	 to	 the	 progression	 in	 cycling	 training	 intensity	
during	the	GET	programme,	as	well	as	 to	 increases	 in	6MWD	and	endurance	cycling	time	after	 the	
training	period.	
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Peak	 work	 rate	 =	 peak	 power	 output	 during	 a	maximal	 incremental	 cycle	 ergometry	 test;	 6MWD	 =	 six	minute	 walking	





















6MWD	(m)	 353	(116)	 388	(113)#	 374	(102)	 407	(105)#	 0.3	(-13	to	14)	 0.967	
Dyspnoea	post	6MWD	 5.4	(2.2)	 5.7	(2.3)	 5.5	(2.2)	 5.4	(2.1)	 0.2	(-0.3	to	0.8)	 0.400	
Leg	effort	post	6MWD	 4.2	(2.3)	 4.3	(2.0)	 4.3	(2.4)	 4.4	(2.0)	 -0.1	(-0.7	to	0.4)	 0.630	
Maximal	exercise	capacity	 Intervention	group	 Control	group	 	 	
Peak	work	rate	(W)	 54	(21)	 64	(26)#	 54	(20)	 59	(22)#	 5.2	(-0.4	to	10.8)	 0.069	
Peak	VO2	(mL/min)	 1,009	(310)	 1,048	(313)	 909	(275)	 966	(323)	 0.01	(-0.09	to	0.11)	 0.881	
Peak	VE	(L/min)	 36	(11)	 37	(11)	 38	(12)	 39	(15)	 -0.5	(-3.4	to	2.3)	 0.703	
Dyspnoea	post	CPET	 6.7	(2.6)	 6.3	(2.7)	 5.9	(2.3)	 6.4	(2.1)	 -0.5	(-1.4	to	0.5)	 0.324	
Leg	effort	post	CPET	 5.8	(2.9)	 6.0	(2.4)	 5.9	(2.2)	 6.1	(2.1)	 -0.1	(-1.0	to	0.8)	 0.836	
Endurance	exercise	
capacity	
Intervention	group		 Control	group		 	 	
Work	rate	(W)	 42	(16)	 44	(18)	 	 	
Endurance	cycle	time	(sec)	 271	(126)	 496	(309)#	 303	(163)	 466	(292)#	 75	(1	to	149)	 0.048	
Dyspnoea	post	cycle	test	 6.1	(2.2)	 6.0	(2.1)	 6.1	(2.2)	 5.9	(2.3)	 -0.3	(-1.0	to	0.4)	 0.405	
Leg	effort	post	cycle	test	 6.0	(1.9)	 5.2	(2.1)	#	 5.5	(2.3)	 5.5	(2.3)	 -0.4	(-1.2	to	0.3)	 0.216	
Dyspnoea	score	at	isotime	 6.1	(2.2)	 3.7	(1.3)#	 5.9	(2.0)	 4.4	(1.9)#	 -0.7	(-1.5	to	-0.01)	 0.049	
Leg	effort	score	at	isotime	 6.1	(1.9)	 4.2	(1.7)	#	 4.9	(2.3)	 4.5	(2.2)	 -0.9	(-1.7	to	0.01)	 0.052	
Data	are	presented	as	mean	(SD)	and	mean	(95%	CI).	Abbreviations:	6MWD	=	six	minute	walking	distance;	Peak	work	rate	=	
peak	 power	 output;	 W	 =	 watts;	 Peak	 VO2	 =	 peak	 oxygen	 uptake;	 Peak	 VE	 =	 peak	 pulmonary	 ventilation;	 CPET	 =	
cardiopulmonary	exercise	test.	Dyspnoea	and	leg	effort	scores	were	evaluated	with	the	modified	CR-10	Borg	scale.	Analyses	
are	based	on	169	(6MWD,	97%	of	completers),	92	(peak	work	rate,	53%	of	completers),	and	139	(endurance	cycle	time,	80%	




















#	 52	(11)	 61	(13)#	 14	(10	to	18)	 <0.001	
PEmax	(cmH2O)	 110	(40)	 127	(52)
#	 104	(30)	 117	(35)#	 3	(-7	to	14)	 0.531	
Endurance	breathing	(sec)	 240	(108)	 593	(270)#	 251	(96)	 413	(236)#	 189	(114	to	265)	 <0.001	
Ti/Ttot	(%)	 31	(17)	 21	(14)#	 34	(19)	 28	(17)#	 -5.6	(-9.3	to	-1.9)	 0.003	
Total	work	(J)	 78	(83)	 258	(153)#	 79	(97)	 159	(162)#	 100	(57	to	142)	 <0.001	
























exercise	 training	 (panel	 A),	 6MWD	 (panel	 B),	 and	 endurance	 cycling	 time	 after	 training	 (panel	 C).	
Tertiles	based	on	improvements	in	PImax	were	defined	as	follows:	1st	tertile:	∆PImax	≤	7	cmH2O	(n=56;	
29%	 intervention	 group	 and	 71%	 control	 group),	 2nd	 tertile	 ∆PImax	 8-20	 cmH2O	 (n=60;	 48%	
intervention	group	and	52%	control	group),	3rd	tertile:	∆PImax	≥	21	cmH2O	(n=55;	78%	intervention	
group	and	22%	control	group).	Data	are	presented	as	mean±SEM.	




